Survodutide (Dual GLP-1/Glucagon Agonist) — Weight & Metabolism

Investigational dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH/NASH, developed by Boehringer Ingelheim.

Overview

This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.

Compound Class

Weight & Metabolism

Mechanism of Action

Activates GLP-1 receptors in the hypothalamus (appetite suppression) and pancreas (glucose-dependent insulin secretion)

Regulatory Status

Not FDA-Approved — Phase 3 clinical trials ongoing (SYNCHRONIZE program)

Evidence Level

emerging